Glucose-regulated insulin production from genetically engineered human non-beta cells

Area of Science:

• Cell Biology
• Endocrinology
• Biotechnology

Background:

• Type 1 diabetes is an autoimmune disease characterized by the destruction of insulin-producing beta cells in the pancreas.
• Current treatments involve lifelong insulin replacement therapy, which can lead to complications.
• Development of functional beta cell surrogates is crucial for advancing diabetes treatment.

Purpose of the Study:

• To develop and characterize novel human cell lines capable of glucose-regulated insulin and C-peptide secretion.
• To identify cell lines suitable for therapeutic applications in type 1 diabetes.
• To create a reliable and scalable source of insulin-producing cells.

Main Methods:

• Stable and constitutive expression of human proinsulin with a furin-cleavable site.
• Glucose-regulated expression of furin to control insulin secretion.
• Cloning of cell lines for uniform transgene integration and expression.
• Characterization of insulin and C-peptide secretion in response to glucose.
• Assessment of biological activity and in vivo efficacy in diabetic animal models.

Main Results:

• Four human cell lines secreting insulin and C-peptide in response to elevated glucose were successfully developed.
• Cloning ensured uniform transgene expression and allowed selection of cell lines with enhanced properties.
• The produced insulin was biologically active and effectively normalized blood glucose levels in diabetic animals.
• These cell lines represent a promising surrogate beta cell for potential therapeutic use.

Conclusions:

• Engineered human cell lines can be developed to mimic pancreatic beta cell function.
• These cell lines demonstrate glucose-responsive insulin secretion and therapeutic potential for type 1 diabetes.
• Further development could lead to a cell-based therapy for diabetes, reducing reliance on exogenous insulin.